Altimmune (ALT) News & Sentiment

Program to Feature Presentations from Renowned KOLs in Obesity, MASH and Two Additional Indications for Pemvidutide following recent IND Clearances by FDA Program to Feature Presentations from Renowned KOLs in Obesity, MASH and Two Additional Indications for Pemvidutide following recent IND Clearances by FDA

GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Leerink Global Healthcare Conference. Details are as follows:

Altimmune's pemvidutide shows promise in treating MASH with obesity, potentially positioning it as a first-in-class drug targeting both liver health and weight loss. Despite past volatility, ALT stock has stabilized, with recent data showing significant weight loss at higher doses, sparking renewed investor interest. Altimmune's Q4 2024 earnings reveal a net loss of $23.2m, with $131.9m in cash, highlighting the company's ongoing financial challenges and reliance on future clinical success.

Altimmune, Inc. (NASDAQ:ALT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Lee Roth - President, Burns McClellan, Investor Relations Advisors Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Greg Weaver - Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Annabel Samimy - Stifel Liisa Bayko - Evercore William Wood - B. Riley Securities Jonathan Wolleben - Citizens JMP Patrick Trucchio - H.C.

ALT5 Sigma honored for delivering enterprise-grade crypto payment solutions that enhance security, compliance, and transaction efficiency LAS VEGAS, NEVADA / ACCESS Newswire / February 26, 2025 / ALT5 Sigma Corporation (Nasdaq:ALTS), a leading fintech innovator specializing in blockchain-powered trading and payment solutions, is proud to announce that it has been named Best Payment Provider at the SiGMA Eurasia Awards 2025. This award recognizes ALT5 Sigma's leadership in digital asset payments, honoring its secure, efficient, and scalable solutions that enable businesses to transact effortlessly with cryptocurrency.

Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career

Now Accepting $TRUMP Coin, Along with Bitcoin, Ethereum, Bitcoin Cash, Dogecoin, Litecoin, and More LAS VEGAS, NV / ACCESS Newswire / February 20, 2025 / Old Glory Bank, a pro-America financial institution, and ALT5 Sigma Corporation ("ALT5") (Nasdaq:ALTS), a leading fintech innovator specializing in blockchain-powered solutions, today announced the expansion of crypto payment options for investors in Old Glory Bank's Regulation A+ (Reg A+) mini-IPO . Along with Bitcoin, Ethereum, Bitcoin Cash, Dogecoin, Litecoin, and other cryptocurrencies, the $TRUMP Coin can now be accepted as a payment method for subscribing to Old Glory Bank's mini-IPO.

ALT5 Pay Merchants can now accept $TRUMP for payments, with seamless USD or stablecoin conversion. LAS VEGAS, NV / ACCESS Newswire / February 18, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS), a leading fintech innovator specializing in blockchain-powered solutions, today announced that the Official $TRUMP Coin has been added to both its ALT5 Prime trading platform and to ALT5 Pay, a cutting-edge cryptocurrency payment platform designed for global merchants.

Altimmune is a single-molecule company currently trading at a $0.5 billion market cap with a favorable risk-reward profile. The company's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH (metabolic dysfunction-associated steatohepatitis). Pemvidutide has successfully completed a Phase 1 trial for a related liver disease but has yet to demonstrate efficacy in the target indication of MASH.